公开(公告)号：US20230159546A1

公开(公告)日：2023-05-25

申请号：US17989103

申请日：2022-11-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jorden Kass ,  Wei Li ,  Hui Cao ,  Jiajun Zhang ,  Xuri Gao ,  Xiaowen Peng ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10

CPC classification number: C07D487/10

Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230115107A1

公开(公告)日：2023-04-13

申请号：US17720654

申请日：2022-04-14

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Xuri Gao ,  Wei Li ,  Jiajun Zhang ,  Xiaowen Peng ,  Hui Cao ,  Jorden Kass ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  C07D487/12 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240207224A1

公开(公告)日：2024-06-27

申请号：US18509403

申请日：2023-11-15

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Jiajun Zhang ,  Xuri Gao ,  Hui Cao ,  Yuk Ming Siu ,  Bin Wang ,  Jiang Long ,  Wei Li ,  Matthew C. Rhodes ,  Xuechao Xing ,  Scott Mitchell ,  Yat Sun Or

IPC: A61K31/395 ,  A61K31/4192 ,  A61K31/4995 ,  A61P31/14 ,  C07D225/04 ,  C07D245/04 ,  C07D255/04 ,  C07D273/02 ,  C07D281/00 ,  C07D285/00 ,  C07D487/08

CPC classification number: A61K31/395 ,  A61K31/4192 ,  A61K31/4995 ,  A61P31/14 ,  C07D225/04 ,  C07D245/04 ,  C07D255/04 ,  C07D273/02 ,  C07D281/00 ,  C07D285/00 ,  C07D487/08

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11970502B2

公开(公告)日：2024-04-30

申请号：US17735203

申请日：2022-05-03

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jiajun Zhang ,  Xiaowen Peng ,  Yat Sun Or

IPC: C07D487/08 ,  C07D498/18

CPC classification number: C07D487/08 ,  C07D498/18

Abstract: The present invention discloses macrocyclic compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11760755B2

公开(公告)日：2023-09-19

申请号：US16892373

申请日：2020-06-04

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xiaowen Peng ,  Xuri Gao ,  Wei Li ,  Hui Cao ,  Byung-Chul Suh ,  Jorden Kass ,  Jiajun Zhang ,  Yat Sun Or

IPC: C07D453/00 ,  C07D487/04 ,  C07D519/00 ,  A61P31/20 ,  A61K38/21 ,  A61K31/5383 ,  A61K45/06 ,  A61K31/519

CPC classification number: C07D453/00 ,  A61K31/519 ,  A61K31/5383 ,  A61K38/21 ,  A61K45/06 ,  A61P31/20 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:




which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20220402926A1

公开(公告)日：2022-12-22

申请号：US17719920

申请日：2022-04-13

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jiajun Zhang ,  Xiaowen Peng ,  Byung-Chul Suh ,  Jorden Kass ,  Xuri Gao ,  Hui Cao ,  Wei Li ,  Joseph D. Panarese ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11236111B2

公开(公告)日：2022-02-01

申请号：US16891401

申请日：2020-06-03

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Xiaowen Peng ,  Wei Li ,  Jorden Kass ,  Hui Cao ,  Byung-Chul Suh ,  Jiajun Zhang ,  Yat Sun Or

IPC: C07D487/20 ,  C07D498/20 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11912714B2

公开(公告)日：2024-02-27

申请号：US17983501

申请日：2022-11-09

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Hui Cao ,  Wei Li ,  Xuri Gao ,  Jiajun Zhang ,  Xiaowen Peng ,  Jorden Kass ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

CPC classification number: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230331734A1

公开(公告)日：2023-10-19

申请号：US18130641

申请日：2023-04-04

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Hui Cao ,  Jiajun Zhang ,  Xuechao Xing ,  Matthew C. Rhodes ,  Xuri Gao ,  Wei Li ,  Yat Sun Or

IPC: C07D487/10

CPC classification number: C07D487/10

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit picornavirus, norovirus or coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230295175A1

公开(公告)日：2023-09-21

申请号：US18122892

申请日：2023-03-17

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Kaicheng Zhu ,  Tao Wang ,  Xin Zhang ,  Xiaowen Peng ,  Ruichao Shen ,  Jiajun Zhang ,  Wei Li ,  Hui Cao ,  Xuri Gao ,  Guoqiang Wang ,  George G. Wu ,  Yat Sun Or

IPC: C07D487/10

CPC classification number: C07D487/10

Abstract: The present invention relates to processes for preparing a compound of Formula (A):




or a pharmaceutically acceptable salt or solvate thereof. Compound of Formula (A) and pharmaceutical compositions are useful as SARS-CoV-2 3CL pro inhibitors.